Here, we have identified for the first time the potential active compounds (L-ascorbyl 2,6-dipalmitate, squalene, and tributyl O-acetylcitrate) and targets (NOS2, MAOB, and PDE3A) of PSM that contributes to its beneficial effects against ARHI. The gene discussed is PDE3A; the disease is presbycusis.